5414x

The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25

: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update

: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth : The full regulatory document can be accessed through

: £13.0 million (+52.9%), driven by AMR and EMEAI growth.

Co-founder and CEO announced he will step down from his role and the board by the end of 2026. Segment Growth : : £13

: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year.

: Introduced next-generation automated flow cell lines and strengthened quality assurance to ISO 13485 standards. Gross Profit : £61

"5414X" is the RNS (Regulatory News Service) identifier for the released by Oxford Nanopore Technologies plc .